Abvc Biopharma (ABVC) EBT Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly EBT Margin came in at 261.69% in Q3 2025, down 13657.0% on a YoY basis from N/an in Q3 2024, and up 99.35% quarter-over-quarter from 40515.11% in Q4 2024.
Powered by 
Analysis
Abvc Biopharma (ABVC) EBT Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has reported EBT Margin for 13 consecutive years, with 261.69% the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, EBT Margin fell 13657.0% year-over-year to 261.69%; the trailing twelve-month figure through Sep 2025 stood at 470.19% (up 52984.0% YoY), and the FY2025 full-year result was 26284.04%, down 2523033.0% from the prior year.
- EBT Margin improved to 261.69% in Q3 2025 per ABVC's latest filing, from 40515.11% in the prior quarter.
- Across five years, EBT Margin topped out at 15585.03% in Q4 2021 and bottomed at 242959.92% in Q1 2024.
- Historically, EBT Margin has averaged 23304.52% across 5 years, with a median of 1981.75% in 2021.
- The widest YoY moves for EBT Margin: up 3557250 bps in 2024, down 24148085 bps in 2024.
- Over 5 years, EBT Margin stood at 15585.03% in 2021, then slumped by 104 bps to 600.69% in 2022, then tumbled by 3937 bps to 24249.38% in 2023, then slumped by 67 bps to 40515.11% in 2024, then surged by 99 bps to 261.69% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 261.69%, 40515.11%, and 125.12% for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -261.69% |
| Dec 31, 2024 | -40,515.11% |
| Sep 30, 2024 | -125.12% |
| Jun 30, 2024 | -988.81% |
| Mar 31, 2024 | -242,959.92% |
| Dec 31, 2023 | -24,249.38% |
| Sep 30, 2023 | -21,210.52% |
| Jun 30, 2023 | -36,561.30% |
| Mar 31, 2023 | -1,479.07% |
| Dec 31, 2022 | -600.69% |
| Sep 30, 2022 | -8,924.51% |
| Jun 30, 2022 | -648.78% |
| Mar 31, 2022 | -24,062.67% |
| Dec 31, 2021 | 15,585.03% |
| Sep 30, 2021 | -1,981.75% |
| Jun 30, 2021 | -6,719.00% |
| Mar 31, 2021 | -473.63% |
| Dec 31, 2020 | -8,128.79% |
| Sep 30, 2020 | -1,883.00% |
| Jun 30, 2020 | -985.68% |